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Abstract 
BACKGROUND: Psoriasis vulgaris is a chronic inflammatory skin disorder that can lead to depression. There is a 
similarity in neurotrophic substance in the pathogenesis of psoriasis and depression; it’s called brain-derived 
neurotrophic factor (BDNF). BDNF level imbalance potentially affects the severity of psoriasis and depression.  
AIM: This study aims to know the correlation between serum BDNF level and depression severity in psoriasis 
vulgaris patient and also the correlation between serum BDNF level and psoriasis vulgaris severity.  
METHODS: This is an analytical cross-sectional study that 23 psoriasis vulgaris patients participated. All 
participants have performed serum BDNF level examination with enzyme-linked immunosorbent assay (ELISA). 
Depression severity assessed with Beck depression inventory-II (BDI-II) and psoriasis severity assessed with 
psoriasis area and severity index. Correlation between all variables was analysed with Spearman’s correlation 
test. 
RESULTS: Serum BDNF level and depression severity are a strongly negative correlation in psoriasis vulgaris 
patients (r = -0.667 with significant value p = 0.001). There is a moderate negative correlation between serum 
BDNF level with psoriasis vulgaris severity (r = -0.595 with significant value p = 0.003).  
CONCLUSION: In psoriasis vulgaris patients, a low level of serum BDNF may increase depression severity and 
psoriasis vulgaris severity. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Psoriasis is a chronic inflammatory skin 
disease with genetic factors may greatly affecting this 
disease [1].
 
Characteristics of psoriasis are a 
disturbance of epidermal proliferation and 
differentiation that involves biochemical, 
immunological, vascular and nervous system [1]. In 
general, it can be assumed that psoriasis, brain-
derived neurotrophic factor (BDNF) and depression 
are related to each other. In psoriasis and depression, 
BDNF level is decreased. This condition may 
contribute to similar pathogenesis between psoriasis 
and depression. Psoriasis can be caused depression, 
as does depression can trigger psoriasis [2], [3]. 
There is a similarity between skin 
embryogenesis and the nervous system, its called 
ectodermal. Its allowed the role of growth factors in 
controlling skin homeostasis and remodelling, in this 
case, the role of neurotrophin [2]. The relationship 
between the nervous system and psoriasis was 
proved by the remission of psoriasis lesions after the 
cutaneous sensory nerve had removed [4], [5]. Some 
studies focused on the role of neurotropic in psoriasis, 
possibly due to activation of mast cells that continue 
into skin inflammation and then stimulate other 
neuroinflammatory cytokines [6]. 
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In psoriasis, epidermal proliferation and 
apoptosis are influenced by neuropeptides and their 
receptors. Through its main receptor tyrosine kinase B 
(TrkB), BDNF plays a role in keratinocyte proliferation 
and apoptosis [2]. BDNF induces keratinocyte 
apoptosis but does not work on psoriatic transit-
amplifying sub-population of basal keratinocytes [2]. 
In line with a low level of BDNF in psoriasis 
patients, research showed that BDNF level in 
depressed patients is also low. Psychological stress 
will reduce BDNF level through activation of the 
hypothalamic-pituitary-adrenal axis and sympathetic-
adrenal-medullary axis which will increase cortisol and 
neuroinflammation cytokines and reduce BDNF level 
[7]. 
The problems of psoriasis are not limited to 
the skin. Psoriasis can result in psychological distress 
and a decrease in the quality of life [1]. Psychological 
stress, social stigma and embarrassment can lead to 
depression. The prevalence of depression in psoriasis 
patients is 10-62% [8]. A cross-sectional study found 
32% of patients with psoriasis suffered from 
depression from a total of 265 psoriasis patients [9]. 
Psoriasis patients have a higher tendency to suffered 
from depression than leprosy, vitiligo and lichen 
planus [8]. Depression in psoriasis patients affects 
treatment adherence which remission is impossible to 
achieve. Based on these many studies, it is interesting 
to investigate the correlation between serum BDNF 
level and depression severity in psoriasis vulgaris 
patients. 
 
 
Methods 
 
This is an analytical cross-sectional study 
conducted from September 2016 to October 2017. 
This study was held at dermatology and venereology 
clinic Adam Malik General Hospital Medan Indonesia. 
The sample was taken using consecutive sampling 
method. This study was approved by the ethical 
commission of Faculty of Medicine Universitas 
Sumatra Utara Medan Indonesia. 
Inclusion criteria in this study were patients 
diagnosed clinically as psoriasis vulgaris, age 20-65 
years old, willing to take part in the study and sign an 
informed consent letter. Exclusion criteria were 
pregnant and breastfeeding patient, using topical 
drugs to treat psoriasis vulgaris such as a topical 
corticosteroid, calcipotriol, tazarotene and tar 2 weeks 
before this study was conducted. And patients who 
used systemic drugs such as methotrexate, acitretin, 
cyclosporine, corticosteroid 6 weeks before this study 
was conducted. Patients who suffered from bipolar 
disorder, schizophrenia and used antidepressant 
drugs are also excluded. 
Blood sampling was taken at 8-9 am to avoid 
variations due to circadian rhythm. Measurement of 
BDNF serum level was done at the Clinical Pathology 
Laboratory of Adam Malik General Hospital Medan 
Indonesia using human brain-derived neurotrophic 
factor kit (R&D
®
, USA) and ELISA method. 
Measurement of depression severity was performed 
using Beck depression inventory-II (BDI-II). In this 
study, psoriasis severity was also evaluated using the 
psoriasis area and severity index (PASI). 
The collected data was analysed to determine 
the relationship between variables using computer 
software. Correlation between serum BDNF level and 
depression severity and psoriasis severity was 
analysed with the Spearman correlation test. 
Significant correlation indicated by p-value ≤ 0.05. 
 
 
Results 
 
Psoriasis vulgaris patients characteristics 
In this study 23 psoriasis vulgaris patients 
were participated and fulfil the inclusion and exclusion 
criteria. Characteristic of subjects were reported 
based on the gender, age, education, psoriasis and 
depression severity (Table 1). 
Table 1: Psoriasis vulgaris patient’s characteristic 
No. Characteristic Amount (n) (%) 
1. Gender   
 Male 12 52.2 
 Female 11 47.8 
2. Age group   
 20-29 3 13 
 30-39 7 30.4 
 40-49 
50-59 
≥ 60 
7 
5 
1 
30.4 
21.7 
4.3 
3. Education   
 Elementary 0 0 
 Junior high school 
High school 
Undergraduate 
2 
10 
11 
8.7 
43.5 
47.8 
4. Psoriasis severity 
Mild 
Moderate  
Severe 
 
13 
4 
6 
 
56,5 
17,4 
26,1 
5. Depression severity 
Minimal 
Mild 
Moderate  
Severe 
 
7 
7 
9 
0 
 
30.4 
30.4 
39.1 
0 
 
The frequency difference between male and 
female patients was only 1 patient (4.4%). Based on 
the age group, the highest frequency are at the group 
30-39 and 40-49 years old and have the same 
frequency of 7 patients (30.4%). The lowest frequency 
is in the age group ≥ 60 years old, who is only 1 
patient (4.3%). Based on education, this study found 
the highest frequency is undergraduate patients that 
are 11 patients (47.8%). The lowest frequency is 
junior high school that is 2 patients (8.7%). It can be 
concluded that the subjects in this study were well-
educated patients. 
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Based on the psoriasis severity, the highest 
frequency in this study was mild psoriasis, that is 13 
patients (56.5%). While the lowest frequency is 
moderate psoriasis, that is 4 patients (17.4%).  
The highest frequency of depression severity 
in this study was moderate depression that is 9 
patients (39.1%).  
 
Correlation between BDNF Levels and 
Depression Severity in Psoriasis Vulgaris 
Patients 
This study found that the average serum 
BDNF level was 912.45 ± 180.94 pg/ml (Table 2). 
Table 2: Correlation between serum brain-derived neurotrophic 
factor level and depression Severity in psoriasis vulgaris 
Patients and psoriasis severity 
1. Serum BDNF level (Mean ± SD) 912,45 ± 180,94 
 p r r
2
 
2.Serum BDNF level and depression severity 0,001 -0,667 0,445 
3. Serum BDNF level and psoriasis severity 0,003 -0,595 0,354 
*Spearman's correlation test. 
 
Serum BDNF level and depression severity 
were analysed with Spearman correlation, the value of 
the correlation coefficient (r) was -0.667 with a 
significance value (p) of 0.001 (Table 2). There is a 
strong negative correlation between serum BDNF 
level with depression severity. The lower serum BDNF 
level, the higher the severity of depression will be [14]. 
The coefficient of determination (r
2
) in this analysis 
was found 45%, which indicate that 45% factor that 
influence severity of depression was serum BDNF 
level, and the remaining 55% are other factors (Table 
2). 
 
 
Discussion 
 
Man and woman have the same opportunity 
to suffered from psoriasis [1], [10]. Psoriasis affects all 
age, but in children, the incidence is low (0.71%) [11]. 
Similar to the study by Kundacki et al., Who reported 
that psoriasis in childhood is rare, only 5.7% under the 
age of 10 years [12]. In this study, we have only 
recruited patients with psoriasis vulgaris at the age of 
more than 20 years old. 
Fathy et al. reported that 90 psoriasis vulgaris 
patients had the average of PASI score was 20.8 ± 
18.8, 70% of patients were categorised as moderate 
to severe psoriasis with a PASI score > 10 [13]. 
In this study, there were no psoriasis vulgaris 
patients with a severe degree of depression. Fatthy et 
al. reported that severe depression was higher in 
psoriasis vulgaris patients [13]. 
Fatthy et al. reported that BDNF level was 
lower in both groups of psoriasis (without depression 
25.2 ± 6.5; with depression 16.9 ± 2.5) compared to 
the healthy control group (26.5 ± 3.6) [13]. BDNF level 
was significantly lower in psoriasis vulgaris patients 
with depression compared to psoriasis patients who 
did not suffer from depression (mean difference 8.3; p 
< 0.001) [13]. BDNF level was also significantly lower 
in psoriasis vulgaris patients with depression and 
depressed patients without psoriasis compared to 
healthy controls (p < 0.0001 and p < 0.001) [13]. The 
mean BDNF level was significantly lower (p < 0.01) in 
the group of psoriasis patients with depression (16.9 ± 
2.5) compared to depressed patients without psoriasis 
vulgaris (21.5 ± 5.8) [13]. 
Duclot et al. reported that low BDNF level was 
known to play a role in depression pathophysiology, 
but can be increased by antidepressant [15]. 
However, BDNF level in serum does not correlate with 
depression severity. Therefore, utilisation of BDNF as 
a biomarker of depression is still unclear [15]. 
The role of BDNF in depression is proven by 
the presence of four things [16]. First, depression 
causes a decrease in BDNF level in the hippocampus 
and the prefrontal cortex. Second, depression triggers 
atrophy of the nerve dendrites in the hippocampus 
and the prefrontal cortex. Third, there is evidence of 
increased BDNF level in the hippocampus and the 
prefrontal cortex after administration of 
antidepressant. Fourth, the BDNF level increased in 
the amygdala and neural accumbent area which 
facilitate symptoms of depression. Therefore, Yu et al. 
concluded that depressive symptoms depend on 
BDNF level in the affected anatomic location [16]. 
BDNF level and psoriasis vulgaris severity 
were analysed with the Spearman correlation test; the 
correlation coefficient (r) was -0.595 with significant 
value (p) 0.003 (Table. 2). This result showed a 
moderate negative correlation between BDNF level 
and psoriasis vulgaris severity. The lower serum 
BDNF level, the higher psoriasis severity will be [14]. 
The coefficient of determination (r
2
) in this analysis 
was found 35%, which indicate 35% factor that 
influences psoriasis severity was serum BDNF level 
and the remaining 65% were influenced by other 
factors.  
Fatthy et al., reported that there was no 
correlation between BDNF level and PASI score (r = 
0.217; p = 0.250) [13]. Similarly, Narbutt et al. 
reported that there was no correlation between BDNF 
level and PASI score [17]. The mean BDNF level in 
their study were 14.5 ng/ml and the mean of PASI 
score was 14.3 (p > 0.05) [17]. 
A study conducted by Brunoni et al. reported 
that there was no difference (p = 0.59) BDNF level in 
patients with mild psoriasis (3649 ± 3653 pg/ml) and 
severe psoriasis (3280 ± 2837 pg/ml) [2]. However, in 
their study psoriasis severity was not assessed with 
the PASI score, but was classified according to the 
presence of psoriatic arthritis and the used of 
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systemic therapy such as methotrexate, cyclosporine, 
mycophenolate mofetil, biological agents and 
phototherapy [2]. Raap et al. reported that there was 
no correlation between BDNF level and PASI score 
[18]. However, in their published article did not 
mention the mean of BDNF level in psoriasis patients, 
maybe because it was not the main purpose of their 
study. 
It can be concluded from this study that the 
lower serum BDNF level, the higher the severity of 
depression and psoriasis will be. Serum BDNF level 
might be considered as a biomarker of depression 
severity as well as a biomarker of psoriasis severity in 
patients with psoriasis vulgaris. BDNF might be the 
new psoriasis treatment target. However, further 
investigations with better design are still needed to 
prove this result. 
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